Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

OP030: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

T. Kobayashi*¹, Y. Suzuki², S. Motoya³, F. Hirai⁴, H. Ogata⁵, H. Ito⁶, N. Sato⁷, K. Ozaki⁷, M. Watanabe⁸, T. Hibi¹

Created: Friday, 22 February 2019, 9:49 AM

OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation

Year: 2017

Source: ECCO'17 Barcelona

Authors: Metwaly A.

Last Modified: Wednesday, 15 March 2017, 2:10 PM by ECCO Administrator

Immunology, Microbiota, HSCT

Files: 1

OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Metwaly A.^*1, Butt L.F.¹, Waldschmitt N.¹, Lagkouvardos I.², Corraliza A.M.³, Mayorgas A.³, Martinez-Medina M.⁴, Allez M.⁵, Panes J.³, Salas A.³, Haller D.^1,2

Created: Wednesday, 20 February 2019, 10:36 AM

OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory molecules

Year: 2018

Source: ECCO '18 Vienna

Authors:

L. Hering¹*, C. Gottier¹, S. Lang¹, B. Becher², G. Rogler¹, M. Scharl¹, M. Spalinger¹

Created: Thursday, 21 February 2019, 9:14 AM

OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study

Year: 2018

Source: ECCO '18 Vienna

Authors:

N.A. Kennedy¹*, G. Heap¹,², B. Hamilton¹, G.J. Walker¹, C. Bewshea¹, S. Bouri³, J. Goodhand¹, PANTS Investigator Consortium, T. Ahmad¹

Created: Thursday, 21 February 2019, 9:14 AM

OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study

Year: 2018

Source: ECCO'18 Vienna

Authors: Kennedy Nicholas A

Created: Friday, 23 March 2018, 12:23 PM

Files: 1

OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Panés J.^*1, D'Haens G.R.², Higgins P.D.R.³, Mele L.⁴, Moscariello M.⁴, Chan G.⁴, Wang W.⁴, Niezychowski W.⁴, Su C.⁴, Maller E.⁴

Created: Wednesday, 20 February 2019, 10:36 AM

OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension study

Year: 2017

Source: ECCO'17 Barcelona

Authors: Panés J.

Last Modified: Wednesday, 15 March 2017, 2:07 PM by ECCO Administrator

Tofacitinib, Crohn's Disease

Files: 1

OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial

Year: 2017

Source: ECCO'17 Barcelona

Authors: Panés J.

Last Modified: Wednesday, 15 March 2017, 2:06 PM by ECCO Administrator

Tofacitinib, Ulcerative Colitis

Files: 1

OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Sandborn W.J.¹, Sands B.E.², Danese S.³, D'Haens G.R.⁴, Vermeire S.⁵, Schreiber S.⁶, Feagan B.⁷, Reinisch W.^8,9, Friedman G.¹⁰, Woodworth D.¹⁰, Zhang H.¹⁰, Lawendy N.¹⁰, Niezychowski W.¹⁰, Su C.¹⁰, Panés J.^*11

Created: Wednesday, 20 February 2019, 10:36 AM

OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab

Year: 2018

Source: ECCO '18 Vienna

Authors:

A. Moens¹,²*, K. van Hoeve²,³, E. Humblet⁴, J.-F. Rahier⁵, P. Bossuyt⁶, S. Dewit⁷, D. Franchimont⁸, E. Macken⁹, J. Nijs¹⁰, A. Posen¹¹, A. Van Hootegem¹², W. Van Moerkercke¹³, S. Vermeire¹,², M. Ferrante¹,²

Created: Thursday, 21 February 2019, 9:14 AM

OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab

Year: 2018

Source: ECCO'18 Vienna

Authors: Moens Annick

Created: Friday, 23 March 2018, 12:23 PM

Files: 1

OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Vermeire S.^*1, De Hertogh G.², Chen G.³, French D.⁴, Huntzicker E.⁴, Van der Aa A.⁵, Van Kaem T.⁵, Harrison P.⁵, Tasset C.⁵, Galien R.⁶, Pan Y.⁴, Feagan B.⁷, Sandborn W.⁸

Created: Wednesday, 20 February 2019, 10:36 AM

OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme

Year: 2018

Source: ECCO '18 Vienna

Authors:

B.E. Sands¹, P.R. Taub², B.G. Feagan³*, A. Armuzzi⁴, G.S. Friedman⁵, M. Moscariello⁵, N. Lawendy⁵, R.D. Pedersen⁵, G. Chan⁵, C.I. Nduaka⁵, D. Quirk⁵, L. Salese⁵, C. Su⁵

Created: Thursday, 21 February 2019, 9:14 AM

OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study

Year: 2017

Source: ECCO'17 Barcelona

Authors: Reinisch W.

Last Modified: Wednesday, 15 March 2017, 2:04 PM by ECCO Administrator

Abrilumab

Files: 1

OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Sandborn W.J.¹, Cyrille M.², Hansen M.B.³, Feagan B.G.⁴, Loftus Jr. E.V.⁵, Rogler G.⁶, Vermeire S.⁷, Cruz M.L.², Yang J.², Sullivan B.A.², Reinisch W.^*8

Created: Wednesday, 20 February 2019, 10:36 AM

OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

Year: 2018

Source: ECCO '18 Vienna

Authors:

M. Calafat¹,²*, M. Mañosa³,⁴, F. Cañete³, J. Panés⁴,⁵, V. García Sánchez⁴,⁶, M. Calvo⁷, F. Rodríguez-Moranta⁸, C. Taxonera⁹, P. Nos⁴,¹⁰, A. López Sanromán¹¹, M.D. Martín Arranz¹², M. Mínguez¹³, J.P. Gisbert⁴,¹⁴, S. García-López¹⁵, R. de Francisco¹⁶, F. Gomollón⁴,¹⁷, X. Calvet⁴,¹⁸, E. Garcia-Planella¹⁹, M. Rivero²⁰, J. Martínez-Cadilla²¹, F. Argüelles²², L. Arias García²³, M. Cimavilla²⁴, Y. Zabana⁴,²⁵, L. Márquez²⁶, A. Gutiérrez⁴,²⁷, G. Alcaín²⁸, P. Martínez Montiel²⁹, J. Lázaro³⁰, D. Busquets³¹, M.F. García Sepulcre³², C. Verdejo³³, F. Bermejo³⁴, M. Mora³⁵, D. Monfort³⁶, P. Romero³⁷, B. Velayos³⁸, C. Rodríguez³⁹, A. Rodríguez⁴⁰, O. Merino⁴¹, A. Rodríguez-Pescador⁴², L. Bujanda⁴,⁴³, Y. Ber⁴⁴, M. Vela⁴⁵, O. Roncero⁴⁶, J.M. Huguet⁴⁷, O. García-Bosch⁴⁸, M. Barreiro-de-Acosta⁴⁹, R.E. Madrigal⁵⁰, L. Ramos⁵¹, M. Van Domselaar⁵², P. Almela⁵³, J. Llaó⁵⁴, A.J. Lucendo⁴,⁵⁵, C. Muñoz Vilafranca⁵⁶, À. Abad⁵⁷, M. Charro⁵⁸, J. Legido⁵⁹, J. Riera¹, S. Khorrami⁶⁰, E. Sesé⁶¹, A.M. Trapero⁶², E. Domènech³,⁴

Created: Thursday, 21 February 2019, 9:14 AM

OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registry

Year: 2018

Source: ECCO'18 Vienna

Authors: Calafat Margalida

Created: Friday, 23 March 2018, 12:23 PM

Files: 1

OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations

Year: 2018

Source: ECCO'18 Vienna

Authors: Walker Gareth

Created: Friday, 23 March 2018, 12:23 PM

Files: 1

OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Sandborn W.J.¹, Cyrille M.², Berner Hansen M.³, Feagan B.G.⁴, Loftus Jr. E.V.⁵, Vermeire S.⁶, Cruz M.L.², Mo M.², Sullivan B.A.², Reinisch W.^*7

Created: Wednesday, 20 February 2019, 10:36 AM